Menu
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 3
Botulinum toxin type A for the management of glabellar rhytids
Authors Tremaine AM
Published 7 April 2010 Volume 2010:3 Pages 15—23
DOI https://doi.org/10.2147/CCID.S6492
Review by Single anonymous peer review
Peer reviewer comments 4
Anne Marie Tremaine, Jerry L McCullough
Department of Dermatology, University of California, Irvine, CA, USA
Abstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic procedures in the United States. There has been research spanning over two decades dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are now two Food and Drug Administration (FDA) approved botulinum toxin type A options in the United States: Botox® and Dysport™, with new advances being made in the field.
Keywords: botulinum toxin type A, glabella, Botox, Dysport, complications, dosing
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.